Peripheral white blood cells (PBMCs)
PBMCs driven into apoptosis through cellular stress have been shown to be highly potent in experimental wound healing, stroke, spinal cord injury, acute and chronic infarction models and prevention of ischemia reperfusion injury.

A systemic formulation derived from such PBMCs is developed as APO-1 (APOSECTM), whereas the topical formulation is named APO-2 (APOSECTM). Both formulations are prepared by a proprietary process from whole blood drawn from healthy donors.